High-risk (Secondary) Acute Myeloid Leukemia
1 clinical trials · Condition
◉ Watch High-risk (Secondary) Acute Myeloid Leukemia
| Record | Firm | Date |
|---|---|---|
| A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia (NCT06182592) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2024-01-01 |
Track High-risk (Secondary) Acute Myeloid Leukemia automatically
Every clearance here is in the API, with alerts when new ones post.